A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (SPIRIT-P2)

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Estimated Enrollment: 360
Study Start Date: December 2014
Estimated Study Completion Date: June 2019
Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Ixekizumab Dosing Regimen 1
- Experimental: Ixekizumab Dosing Regimen 2
- Placebo Comparator: Placebo